These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 28947028)

  • 1. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
    Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
    Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
    Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
    Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
    Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
    Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
    Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.
    Biondini D; Balestro E; Lacedonia D; Cerri S; Milaneschi R; Luppi F; Cocconcelli E; Bazzan E; Clini E; Foschino Barbaro MP; Gregori D; Cosio MG; Saetta M; Spagnolo P
    Sci Rep; 2018 Apr; 8(1):5961. PubMed ID: 29654244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.